In addition, we have shown that the RGC reprogramming efficiency from MG by TFs is similar in both young and aged Brn3b null mutant mice, making it feasible to treat not only young but also aged patients with glaucoma and other optic neuropathies by this regeneration strategy. The gene discussed is POU4F2; the disease is glaucoma.